Express Pharma

China grants conditional approval for Merck’s COVID treatment

Molnupiravir, developed by Merck, is approved to be used in adult patients who have mild-to-medium COVID infection and a high risk of progressing to severe cases

2 306

China has granted conditional approval for the import of Merck’s COVID-19 treatment Molnupiravir, China’s medical products regulator said today.

Molnupiravir, developed by Merck, is approved to be used in adult patients who have mild-to-medium COVID infection and a high risk of progressing to severe cases, according to China’s National Medical Products Administration.

Edits by EP News Bureau

 

- Advertisement -

2 Comments